Amlodipino Argenol may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Amlodipino Argenol in the following countries:
International Drug Name Search
Torrem may be available in the countries listed below.
Torasemide is reported as an ingredient of Torrem in the following countries:
International Drug Name Search
Reducing secretions in the mouth, throat, airway, and stomach before surgery. It is used before and during surgery to block certain reflexes and to protect against certain side effects of some medicines. It is also used along with other medicines to treat peptic ulcers. It may also be used for other conditions as determined by your doctor.
Robinul is an anticholinergic. It works by blocking the activity of a certain substance (acetylcholine) in the body, which decreases secretions and decreases side effects caused by medicines that may increase the action of acetylcholine in the body.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Robinul. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Robinul. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Robinul may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Robinul as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Robinul.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Bloated feeling; blurred vision; constipation; decreased sweating; dizziness; drowsiness; dry mouth; dry skin; enlarged pupils; headache; loss of taste; nausea; nervousness; pain, swelling, or redness at the injection site; sleeplessness; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; decreased sexual ability; diarrhea; difficulty focusing the eyes; difficulty urinating; excitement; fainting; fast, slow, or irregular heartbeat; fever; seizures; severe or persistent dizziness, light-headedness, or headache; shortness of breath; unusual weakness; vomiting.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Robinul side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; convulsions; difficulty breathing; disorientation; dry mouth; enlarged pupils; excessive thirst; flushed, hot, dry skin; muscle weakness; nausea; restlessness; seizures; unusual dizziness or drowsiness; vomiting.
Robinul is usually handled and stored by a health care provider. If you are using Robinul at home, store Robinul as directed by your pharmacist or health care provider. Keep Robinul out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Robinul. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: Cyclosporine eent
Class: Anti-inflammatory Agents, Miscellaneous
VA Class: IM600
Chemical Name: Cyclo[[(E) - (2S,3R,4R) - 3 - hydroxy - 4 - methyl - 2 - (methylamino) - 6 - octenoyl] - l - 2 - aminobutyryl - N - methylglycyl - N - methyl - l - leucyl - l - valyl - N - methyl - l - leucyl - l - alanyl - d - alanyl - N - methyl - l - leucyl - N - methyl - l - leucyl - N - methyl - l - valyl]
CAS Number: 59865-13-3
Topical immunomodulator; systemic immunosuppressive agent.1 2 3 5 6 7 8 10
Used to increase tear production in adults whose tear production presumably is suppressed secondary to ocular inflammation related to keratoconjunctivitis sicca.1
Increased tear production not observed in patients already receiving topical anti-inflammatory agents or using punctal plugs.1
For ophthalmic use only.1 Not for injection.1 Not for subconjunctival injection or introduction directly into the anterior chamber of the eye.1 4
Apply topically to the eye as an ophthalmic emulsion.1
Avoid contamination of emulsion container.1
Invert unit-dose vial a few times before use to obtain a uniform, opaque, white emulsion.1
Preservative-free emulsion is for single use only in one or both eyes; discard any unused portion immediately after administration.1
Remove contact lenses prior to administration; may reinsert lenses 15 minutes after dose.1
When used concomitantly with artificial tears, administer ophthalmic preparations at least 15 minutes apart.1
1 drop of a 0.05% emulsion into each eye twice daily, approximately 12 hours apart.1
Known hypersensitivity to cyclosporine or any ingredient in the formulation.1
Active ocular infections.1
Safety and efficacy not established in patients with history of herpes keratitis.1
Category C.1
Distributed into milk after systemic administration; it is not known whether distributed into milk after topical application to the eye.1 Caution advised if used in nursing women.1
Safety and efficacy not established in children <16 years of age.1
No substantial differences in safety and efficacy relative to younger adults.1
Ocular burning, conjunctival hyperemia, discharge, epiphora, ocular pain, foreign body sensation, pruritus, stinging, visual disturbance (e.g., blurring).1
No formal drug interaction studies to date.9
Blood cyclosporin A concentrations were below quantitation limit (0.1 ng/mL) after topical application of cyclosporine 0.05% emulsion to the eye twice daily for up to 12 months.1 7 No detectable drug accumulation in blood during 12 months of treatment.1 7
Not known whether distributed into milk after topical application to the eye.1
15–25°C.1
Exact mechanism of action not fully elucidated, but thought to act as a partial immunomodulator with anti-inflammatory effects when administered topically to the eye.1 2 3 5 6 7 8 10
Topical application to the eye reduces cell-mediated inflammatory responses associated with inflammatory ocular surface diseases.2 3
Exhibits immunosuppressive activity when administered systemically.1
Importance of learning and adhering to proper administration techniques to avoid contamination of the product.1
Importance of administering ophthalmic emulsion immediately after opening single-use vial and discarding any unused portion immediately after administration.1
Importance of not wearing contact lenses in presence of decreased tear production.1 If contact lenses are worn, importance of removing lenses prior to administration and delaying reinsertion of lenses for 15 minutes after instillation.1
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
If using artificial tears and ophthalmic cyclosporine, importance of allowing at least 15 minutes to elapse between administration.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Ophthalmic | Emulsion | 0.05% | Restasis (preservative-free) | Allergan |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Restasis 0.05% Emulsion (ALLERGAN): 30/$146.62 or 90/$411.8
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Allergan, Inc. Restasis (cyclosporine) ophthalmic emulsion 0.05% prescribing information. Irvine, CA; 2002 Dec.
2. Sall K, Stevenson OD, Mundorf TK et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000; 107:631-9. [IDIS 453300] [PubMed 10768324]
3. Stevenson D, Tauber J, Reis BL et al. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. A dose-ranging randomized trial. Ophthalmology. 2000; 107:967-74. [IDIS 446941] [PubMed 10811092]
4. Allergan, Inc, Irvine, CA: Personal communication.
5. Laibovitz R, Solch S, Andriano K et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993; 12:315-23. [PubMed 8339560]
6. Tauber J, for the Cyclosporine Study Group. A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. Adv Exp Med Biol. 1998; 438:969-72. [PubMed 9634996]
7. Small DS, Acheampong A, Reis B et al. Blood cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002; 18:411-8. [PubMed 12419092]
8. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120:330-7. [IDIS 478231] [PubMed 11879137]
9. Allergan, Inc. Restasis (cyclosporine ophthalmic emulsion) 0.05% formulary kit. Irvine, CA; 2003.
10. Anon. Ophthalmic cyclosporine (Restasis) for dry eye disease. Med Lett Drugs Ther. 2003; 45:42-3. [PubMed 12766701]
Selumito may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Selumito in the following countries:
International Drug Name Search
